Depatuxizumab mafodotin

Depatuxizumab mafodotin (also known as ABT-414) is an antibody-drug conjugate designed to deliver the cytotoxic agent monomethyl auristatin F (MMAF) to cells expressing the Epidermal Growth Factor Receptor (EGFR). It is being developed by AbbVie for the treatment of glioblastoma.

Mechanism of Action

Depatuxizumab mafodotin targets the EGFR, a protein that is overexpressed in many types of cancer, including glioblastoma. The drug is composed of an antibody that binds to the EGFR, linked to the cytotoxic agent MMAF. Once the drug binds to the EGFR on the surface of a cancer cell, it is internalized and the MMAF is released, leading to cell death.

Clinical Trials

Depatuxizumab mafodotin has been evaluated in several clinical trials for the treatment of glioblastoma. In a Phase II trial, the drug showed promising results, with a median overall survival of 7.3 months in patients with recurrent glioblastoma. However, in a Phase III trial, the drug did not meet its primary endpoint of improving overall survival compared to temozolomide.

Side Effects

Common side effects of depatuxizumab mafodotin include fatigue, nausea, headache, and constipation. Serious side effects can include eye problems, such as blurred vision or vision loss.

See Also

• Antibody-drug conjugate
• Epidermal Growth Factor Receptor
• Glioblastoma
• Monomethyl auristatin F
• Clinical trial

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia